News

The company may sell its common stock to Fusion Capital from time to time over a 24-month period after the Securities and Exchange Commission (SEC) has declared effective

The milestone shows Epix and Cystic Fibrosis Foundation Therapeutics’s (CFFT) successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR)

This technology was patented in Canada in May 2007 and is the third new patent awarded to Kane within the last twelve months. This brings the company’s estate

Banner’s nimodipine 30mg capsules are the AB-rated generic equivalent of Bayer’s Nimotop 30mg capsules, and are indicated for the treatment of subarachnoid hemorrhage, a form of cerebral bleed

Under the collaboration, BioSeek will apply its BioMAP Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs in the fields of

Under the Agreement, Zoll is licensing to Laerdal non-exclusive worldwide rights under patents owned by or licensed to Zoll covering feedback in connection with cardiopulmonary resuscitation (CPR), and

Under the terms of the license, Sienna gains worldwide exclusive rights within a defined field to Geron-controlled intellectual property to detect telomerase activity for the cancer in vitro

Under the collaboration, the parties will evaluate engraftment and function of StemCells’s HuCNS-SC cells in the same rat model preparatory to planned clinical trials. The research, which is

Patients in the Phase III trials who have been receiving the 1,200-mcg dose will now receive a 900-mcg dose. The change is based on recommendations made by the